ERCC5 and cancer: Overall, significantly elevated cancer risk was found when all studies were pooled into the meta-analysis of XPG Asp1104His (dominant model: OR = 1.05, 95% CI = 1.00–1.10; Asp/His versus Asp/His: OR = 1.06, 95% CI = 1.01–1.11).